South Dakota AG Says Medical Marijuana Law Already Meets Rescheduling

South Dakota's opinion says no rewrite is needed

South Dakota's attorney general concluded that the state's medical marijuana laws already satisfy federal rescheduling, so lawmakers and regulators don't have to amend them. MJBizDaily reported the opinion on Oct. 14 and described it as one that other states may heed.

CannIntel hasn't reviewed the full text of the opinion. The analysis below rests on MJBizDaily's report and on the federal framework it addresses.

Still, the headline conclusion is clear. Do nothing, and you're compliant.

Why a one-state opinion carries national weight

Attorney general opinions are generally persuasive rather than binding on courts, but regulators in other states can borrow the reasoning. Every state with a medical program faces the same question once marijuana moves under the federal Controlled Substances Act. Does our statute need to change?

South Dakota's answer is no, and that's the cheapest answer available. A state that adopts it skips a special session and an emergency rulemaking, and it doesn't have to put out a fresh round of license-holder guidance. Agencies in a dozen capitals will read this opinion closely, and some will cite it.

What rescheduling changes, and what it leaves alone

Moving marijuana from Schedule I to Schedule III under 21 U.S.C. § 812 changes federal classification, not the legal basis of state medical programs. Those programs exist under state law. A federal reclassification doesn't automatically rewrite them.

The biggest financial effect sits elsewhere. Section 280E of the tax code denies ordinary business deductions to traffickers in Schedule I and II substances, and a Schedule III classification would take marijuana out of that provision's reach. That's a federal tax question for operators and their accountants. It doesn't ask anything of a state licensing agency.

Schedule III also doesn't make a state-licensed dispensary federally compliant by itself. Prescribing, dispensing and manufacturing rules under the Controlled Substances Act still apply to Schedule III drugs, and the DEA still administers them. The state-federal gap narrows. It doesn't close.

Where other states could still have to act

The risk sits in state statutes that borrow federal definitions or schedules by reference. If a state defines marijuana by pointing to the federal schedule, or ties its program to Schedule I status, rescheduling could create real drafting problems.

That's the test every state attorney general will now run on their own code, and South Dakota's opinion suggests its statutes passed. Whether the same holds elsewhere depends on how each legislature wrote its definitions, and states drafted them very differently. Some programs were built on explicit state-level definitions. Others lean on federal cross-references that nobody expected to matter.

Adult-use states face a separate wrinkle. Rescheduling to Schedule III doesn't create a federal framework for recreational sales, and the South Dakota opinion, as reported, speaks only to medical marijuana.

The hemp and THCA problem rescheduling doesn't touch

Federal rescheduling covers marijuana, while hemp remains defined separately by THC content, and that is where the delta-9 versus total THC fight lives. The 2018 Farm Bill defined hemp as cannabis with no more than 0.3% delta-9 THC on a dry-weight basis. Because THCA decarboxylates into delta-9 THC when heated, a flower can test compliant on delta-9 alone and still deliver intoxicating levels once smoked.

The chemistry is simple. THCA converts at a ratio of roughly 0.877 by molecular weight, so a flower with high THCA carries substantial potential delta-9 even when its raw delta-9 reading is near zero. Congress moved in November 2025 to redefine hemp around total THC, with the change taking effect a year later.

None of that gets resolved by a Schedule III decision or by South Dakota's opinion. A state can be fully compliant on medical marijuana and still face open questions about THCA flower, isomerized products like delta-8 and how its labs report results.

What operators and patients should watch

Medical patients in South Dakota should see no change in program rules, while operators elsewhere should wait for their own attorneys general before assuming the same result. The opinion is a signal, not a nationwide ruling. Each state's statutory text decides its own outcome.

For full background on this story, see the CannIntel topic hub on DEA marijuana rescheduling. Operators should also watch for guidance from state regulators on whether inventory tracking, testing and licensing rules need any technical conforming edits.

This is unsettled. Expect enforcement to vary by state, especially at the hemp-marijuana boundary, and watch for the next attorney general to publish an opinion that either echoes South Dakota or breaks from it.